BR112015027394A8 - derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2 - Google Patents

derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2

Info

Publication number
BR112015027394A8
BR112015027394A8 BR112015027394A BR112015027394A BR112015027394A8 BR 112015027394 A8 BR112015027394 A8 BR 112015027394A8 BR 112015027394 A BR112015027394 A BR 112015027394A BR 112015027394 A BR112015027394 A BR 112015027394A BR 112015027394 A8 BR112015027394 A8 BR 112015027394A8
Authority
BR
Brazil
Prior art keywords
pyrrolo
receptor agonists
pyrimidine derivatives
compound
formula
Prior art date
Application number
BR112015027394A
Other languages
English (en)
Other versions
BR112015027394A2 (pt
Inventor
Kimbara Atsushi
Rogers-Evans Mark
Nettekoven Matthias
Roever Stephan
Schulz-Gasch Tanja
Grether Uwe
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112015027394A2 publication Critical patent/BR112015027394A2/pt
Publication of BR112015027394A8 publication Critical patent/BR112015027394A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

1/1 resumo derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2 a invenção refere-se a um composto da fórmula (i) em que a e r1 a r3 são definidos como na descrição e nas reivindicações. o composto da fórmula (i) pode ser usado como um medicamento.
BR112015027394A 2013-05-02 2014-04-29 derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2 BR112015027394A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13166296 2013-05-02
PCT/EP2014/058648 WO2014177527A1 (en) 2013-05-02 2014-04-29 Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists

Publications (2)

Publication Number Publication Date
BR112015027394A2 BR112015027394A2 (pt) 2017-07-25
BR112015027394A8 true BR112015027394A8 (pt) 2018-01-30

Family

ID=48190401

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015027394A BR112015027394A8 (pt) 2013-05-02 2014-04-29 derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2

Country Status (35)

Country Link
US (1) US9580435B2 (pt)
EP (1) EP2991988B1 (pt)
JP (1) JP6454689B2 (pt)
KR (1) KR20160002857A (pt)
CN (1) CN105164133B (pt)
AR (1) AR096153A1 (pt)
AU (1) AU2014261546B2 (pt)
BR (1) BR112015027394A8 (pt)
CA (1) CA2907691A1 (pt)
CL (1) CL2015003196A1 (pt)
CR (1) CR20150555A (pt)
CY (1) CY1119114T1 (pt)
DK (1) DK2991988T3 (pt)
EA (1) EA028123B1 (pt)
ES (1) ES2635632T3 (pt)
HK (1) HK1213559A1 (pt)
HR (1) HRP20171099T1 (pt)
HU (1) HUE035333T2 (pt)
IL (1) IL242162B (pt)
LT (1) LT2991988T (pt)
MA (1) MA38555B1 (pt)
MX (1) MX2015014081A (pt)
MY (1) MY182237A (pt)
NZ (1) NZ712030A (pt)
PE (1) PE20160039A1 (pt)
PH (1) PH12015502409B1 (pt)
PL (1) PL2991988T3 (pt)
PT (1) PT2991988T (pt)
RS (1) RS56313B1 (pt)
SG (1) SG11201509029PA (pt)
SI (1) SI2991988T1 (pt)
TW (1) TWI680129B (pt)
UA (1) UA116801C2 (pt)
WO (1) WO2014177527A1 (pt)
ZA (1) ZA201507008B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3483163B1 (en) 2013-09-06 2021-06-23 F. Hoffmann-La Roche AG Triazolo[4,5-d]pyrimidine derivatives as cb2 receptor antagonists
EP3215506B1 (en) * 2014-11-07 2019-01-02 F.Hoffmann-La Roche Ag Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
WO2017220516A1 (en) 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
MY197244A (en) * 2016-06-23 2023-06-07 Hoffmann La Roche [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor
CN109311886B (zh) 2016-06-23 2021-11-09 豪夫迈·罗氏有限公司 [1,2,3]三唑并[4,5-d]嘧啶衍生物
EP3475283B1 (en) 2016-06-23 2021-08-11 F. Hoffmann-La Roche AG Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives
CN116438200A (zh) 2020-09-10 2023-07-14 普雷西里克斯公司 针对fap的抗体片段
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004502642A (ja) 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
WO2003082191A2 (en) 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
DE10219435A1 (de) 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
AR042667A1 (es) * 2002-12-26 2005-06-29 Taisho Pharmaceutical Co Ltd Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
MX2008012400A (es) * 2006-03-30 2008-10-10 Irm Llc Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
PT2155747E (pt) * 2007-05-10 2012-12-19 Ge Healthcare Ltd Imidazol(1,2-a)piridinas e compostos relacionados com actividade nos receptores de canabinóides cb2
WO2009032754A2 (en) * 2007-08-31 2009-03-12 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
WO2009051705A1 (en) 2007-10-18 2009-04-23 Merck & Co., Inc. Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
IN2012DN02577A (pt) * 2009-10-15 2015-08-28 Pfizer
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
WO2014005968A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Novel adamantyl derivatives as cannabinoid receptor 2 agonists
KR20150091080A (ko) 2012-12-07 2015-08-07 에프. 호프만-라 로슈 아게 Cb2 작용제로서 유용한 피리딘-2-아마이드
ES2621958T3 (es) 2012-12-07 2017-07-05 F. Hoffmann-La Roche Ag Derivados de pirazina como agonistas receptores de CB2
MY179412A (en) 2012-12-07 2020-11-05 Hoffmann La Roche Pyridine-2-amides useful as cb2 agonists
JP6426618B2 (ja) 2012-12-07 2018-11-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規なピリジン誘導体
PE20151539A1 (es) 2013-03-07 2015-10-28 Hoffmann La Roche Nuevos derivados de pirazol
KR102330794B1 (ko) 2013-05-02 2021-11-26 에프. 호프만-라 로슈 아게 Cb2 수용체 작용제로서의 퓨린 유도체

Also Published As

Publication number Publication date
CY1119114T1 (el) 2018-02-14
US20160046637A1 (en) 2016-02-18
PT2991988T (pt) 2017-07-25
CN105164133B (zh) 2018-02-13
MA38555B1 (fr) 2018-04-30
PL2991988T3 (pl) 2017-10-31
AU2014261546A1 (en) 2015-09-24
AR096153A1 (es) 2015-12-09
ZA201507008B (en) 2017-08-30
EA201591939A1 (ru) 2016-03-31
TWI680129B (zh) 2019-12-21
IL242162B (en) 2019-06-30
HUE035333T2 (en) 2018-05-02
PH12015502409A1 (en) 2016-02-22
PH12015502409B1 (en) 2016-02-22
CA2907691A1 (en) 2014-11-06
NZ712030A (en) 2021-03-26
DK2991988T3 (en) 2017-08-21
MA38555A1 (fr) 2017-09-29
HK1213559A1 (zh) 2016-07-08
JP2016517874A (ja) 2016-06-20
TW201522343A (zh) 2015-06-16
CL2015003196A1 (es) 2016-06-03
BR112015027394A2 (pt) 2017-07-25
CR20150555A (es) 2015-11-20
LT2991988T (lt) 2017-08-10
EA028123B1 (ru) 2017-10-31
AU2014261546B2 (en) 2018-01-18
KR20160002857A (ko) 2016-01-08
MX2015014081A (es) 2015-12-11
SI2991988T1 (sl) 2017-09-29
ES2635632T3 (es) 2017-10-04
SG11201509029PA (en) 2015-12-30
JP6454689B2 (ja) 2019-01-16
EP2991988B1 (en) 2017-05-31
HRP20171099T1 (hr) 2017-10-06
RS56313B1 (sr) 2017-12-29
WO2014177527A1 (en) 2014-11-06
CN105164133A (zh) 2015-12-16
MY182237A (en) 2021-01-18
PE20160039A1 (es) 2016-01-28
UA116801C2 (uk) 2018-05-10
US9580435B2 (en) 2017-02-28
EP2991988A1 (en) 2016-03-09

Similar Documents

Publication Publication Date Title
BR112015027394A2 (pt) derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2
BR112014011055A2 (pt) novos derivados de [1,2,3]triazolo[4,5-d]pirimidina
BR112015020795A2 (pt) derivados de pirazol novos
BR112015012919A2 (pt) novos derivados de piridina
BR112013031463A2 (pt) piridina-2-amidas úteis como agonistas de cb2
BR112015013124A2 (pt) novos derivados de piridina
BR112015009600A2 (pt) piridina-2-amidas úteis como agonistas cb2
BR112015027396A2 (pt) derivados de purina como agonistas do receptor de cb2
CR20160076A (es) NUEVOS DERIVADOS DE TRIAZOLO[4,5-d]PIRIMIDINA
BR112015024272A2 (pt) novos derivados de piridina
BR112016002459A8 (pt) Derivados de benzimidazolil-metil ureia como agonistas receptores de alx
BR112015023161A8 (pt) derivados de piridin-4-ila
BR112015009603A2 (pt) novos derivados de pirazina
BR112012030473A2 (pt) pesticidas baseados em derivados pirrolidina espiroheterocíclicos
BR112015003655A2 (pt) composto; uso de um composto; e composição farmacêutica
BR112014012479A2 (pt) derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas das agonistas de receptor 2 de canabinóide
BR112018011562A2 (pt) novos derivados de fenil
BR112014016803A2 (pt) amidas macrocíclicas como inibidoras de protease
BR112018075143A2 (pt) derivados de [1,2,3] triazolo [4,5-d] pirimidina com afinidade para o receptor de canabonóide tipo 2
BR112015030824A2 (pt) novos derivados de tetrazolona
BR112014019220A8 (pt) Novos derivados de pirrolidina
BR112015010469A2 (pt) derivados de imidazopiridina
BR112012030414A2 (pt) derivados 1,8-diazaespiro[4.5]decano-2,4-diona úteis como pesticidas
BR112015020611A2 (pt) compostos de carboxamida

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2668 DE 22-02-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.